Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg slashes B&M target price but remains upbeat

(Sharecast News) - Berenberg has slashed its target price for B&M by almost a quarter after a profit warning from the discount retailer this week, but kept a 'buy' rating on the stock on the back of its "deep value". On Tuesday, the company guided to first-half adjusted EBITDA of £198m for the 26 weeks to 27 September, down from £274m the year before, and a full-year result of £510m-560m, down from £620m previously.

Chief executive Tjeerd Jegen, who joined in June, said the company's operational execution has been "weak" and announced the launch of a 'Back to B&M Basics' plan focused on returning the UK business - which accounts for the bulk of group revenues - to sustainable like-for-like growth.

"B&M's H1 2026 update on 7 October delivered the cut to guidance under the new CEO that many had feared. That said, we think the news was largely already reflected in the group's low valuation (FY1 PER 8.5x), and the rebasing of expectations has the potential to serve as a 'clearing event'," Berenberg said in a note on Friday.

The broker said the company's "strong foothold" in the UK discount retail sector provides a firm foundation for the 'Back to B&M Basics' plan, which includes price cuts on key value items, resetting its 'Managers Specials' promotions strategy, refocusing product ranges.

"It will take time for the benefits to flow, and execution is key, yet we are encouraged by the decisiveness of the actions already taken. The deep value offered by the shares (including a c9% FCF yield) gives little credit for any profit recovery, in our view, and the c9% total dividend yield pays investors well for waiting."

Berenberg reduced its target price from 590p to 450p, which still represents major upside from Friday afternoon's 232.7p level, up 0.9% on the day.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.